Keywords: Amylin, Takeda, Obesity, Research, Licensing

Amylin could earn over $1 billion from deal with Takeda to co-develop obesity drugs

Article | 02 November 2009

Print This

The USA’s Amylin Pharmaceuticals has signed a deal with Japan’s largest drugmaker, Takeda Pharmaceutical, which could earn the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in